Status
Conditions
Treatments
About
This multi-site study will be done across Hepatobiliary and Pancreatic Surgery Department at Cho Ray Hospital and University and Pharmacy Center. Patients who are diagnosed with periampullary cancer from August 2021 to August 2023 will be underwent pancreaticoduodenectomy. We will follow-up for their pancreatic fistula and bleeding complication and analysis some risk factors.
Full description
The investigator will conduct this study at both site at the same time: Cho Ray Hospital and University and Pharmacy Center. The investigator will directly consult the patient to participate in the study, collect the preoperative information, intraoperative protocol and postoperative data. The investigator will statically analysis the incident of the morbidity (mainly for pancreatic fistula and bleeding), and invest some risk factors relating to those complications.
Plan for conducting the study:
Data analysis
Sample size:
• The investigator expect approximately 100 patients in the first year in both centers. And the investigator hope at least 110 patients in the whole conducting time.
Plan for missing data:
• The investigator will directly collect the patient information before the operation, observe the operation process and follow-up the postoperative during. Investigator will remove any case that missing preoperative information, operative data or post-operative laboratory test.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients diagnosed with periampullary cancer meet the following criteria:
Exclusion criteria
Loading...
Central trial contact
TruongQuoc Vo, Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal